

Box seq

GAU 1642 WD

Docket No.: 41956-DIV

FEB 24 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: David E. Fisher

EXAMINER: S. Ungar

SERIAL NO.: 09/ 229,283

GROUP: 1642

FILED: January 13, 1999

FEB 28 2000

TECH CENTER 1600/2900



FOR: USE OF MICROPTHALMIA FOR DIAGNOSIS, PROGNOSIS, AND/OR TREATMENT OF MELANOMA

The Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Certificate of Mailing

I hereby certify that the following items are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to BOX SEQUENCE, Commissioner of Patents and Trademark, Washington, DC 20231, on this 17<sup>th</sup> day of February, 2000:

1. Computer Readable Copy Containing Nucleotide Sequence;
2. Paper Copy Containing Nucleotide Sequence;
3. Statement that "Sequence Listing" and Computer Readable Copy are the same and/or that Papers Submitted Includes No New Matter;
4. Transmittal of Substitute Specification Sheets;
5. Substitute Specification Sheets.

Nicole L. M. Valtz  
Nicole L. M. Valtz

OR

☐ This substitute specification is being voluntarily submitted, in order to facilitate the processing of the application.

3. As required by 37 C.F.R. § 1.125, the undersigned states that the substitute specification transmitted herewith contains no new matter.

  
SIGNATURE OF PRACTITIONER

Ronald I. Eisenstein  
(type or print name of practitioner)

Nixon Peabody LLP  
101 Federal Street  
P.O. Address

Boston, Massachusetts 02110

Reg. No. 30,628

Tel. No. (617) 345-6054

Customer No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David E. Fisher  
Serial No.: 09/229,283  
Filed: January 13, 1999  
For: USE OF MICROPHthalmia FOR DIAGNOSIS, PROGNOSIS,  
AND/OR TREATMENT OF MELANOMA  
Group No.: 1642  
Examiner S. Ungar

Box Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231



TRANSMITTAL OF SUBSTITUTE SPECIFICATION SHEETS (37 C.F.R. § 1.125)

NOTE: A substitute specification, excluding the claims, may be filed at any point up to payment of the issue fee if it is accompanied by items indicated below. See 37 C.F.R. § 1.125(b).

1. Enclosed are substitute specification sheets 33-38 for pages 33-35 of the originally filed specification in this application.

NOTE: The substitute specification must be submitted in clean form without markings as to amended material. 37 C.F.R. § 1.125(c).

2. (complete the following applicable item)

[X] This substitute specification is submitted, in response to a requirement by the Examiner. Namely, filing of SEQUENCE LISTING.

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a))


I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Nicole L. M. Valtz  
(type or print name of person certifying)

Date: 2/17/2000.